Rani Therapeutics (RANI)
Nasdaq Market Open
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing technology intended to make biologic medicines available through oral dosing. Its work focuses on a long-standing challenge in healthcare: many large-molecule drugs, including proteins, peptides, antibodies, and oligonucleotides, are highly effective but typically require injection or intravenous infusion because they are broken down in the digestive system.
The company’s core platform is the RaniPill capsule, a proprietary drug-delivery system designed to be swallowed like a conventional pill while delivering biologic payloads in the gastrointestinal tract. The aim is to provide an alternative to subcutaneous injections and IV administration, potentially improving patient convenience, adherence, and the overall treatment experience for chronic conditions that require repeated dosing.
Rani’s technology is intended to be adaptable across a range of drug classes rather than tied to a single molecule. This platform approach gives the company opportunities to pursue its own therapeutic programs while also supporting potential collaborations with pharmaceutical and biotechnology partners that have injectable biologics in their portfolios.
The company is also developing RaniPill HC, a version of the platform intended to handle liquid drug payloads and support high bioavailability. As a clinical-stage business, Rani Therapeutics’ prospects depend on the success of its studies, the performance of its delivery system in humans, regulatory progress, manufacturing execution, and its ability to demonstrate that oral biologic delivery can be both safe and commercially useful.
Last updated
- Market Cap
- 98.9M
- P/E
- —
- P/FCF
- —
- P/S
- 31.21
- Enterprise Value
- 89.26M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 2051 RINGWOOD AVENUE, SAN JOSE, CA, 95131
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
Rani Therapeutics to Participate in May Investor Conferences
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
Rani Therapeutics to Participate in September Investor Conferences
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
Rani Therapeutics to Participate in August Investor Conferences
Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
Rani Therapeutics to Present at the Jefferies Healthcare Conference
Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 98.9M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 89.26M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 3.48
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 31.21
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -2.64
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 28.17
- EPS
- -0.26
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -17.11M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -103.65%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -56.75%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 3.4
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 3.4
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.7
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.01M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 0.88
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 1.71M | 1.46M | — | — | 172K |
| Gross profit | 1.71M | 1.46M | — | — | 172K |
| Operating income | -8.34M | -8.54M | -7.26M | -10.51M | -12.01M |
| EBITDA | -8.18M | -8.35M | -7.03M | -10.27M | -11.76M |
| Net income | -7.03M | -10.31M | -5.41M | -6.69M | -7.26M |
| Basic EPS | -0.04 | 0.05 | -0.12 | -0.18 | -0.22 |
| Diluted EPS | -0.04 | 0.05 | -0.12 | -0.18 | -0.22 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 51.88M | 58.62M | 10.14M | 16.9M | 24.13M |
| Total liabilities | 16.34M | 17.11M | 22.11M | 26.05M | 29.47M |
| Total equity | 35.54M | 41.51M | -11.97M | -9.15M | -5.35M |
| Cash & equivalents | 9.64M | 18.62M | 4.14M | 10.22M | 10.11M |
| Current assets | 47.09M | 53.32M | 4.96M | 11.07M | 17.78M |
| Current liabilities | 13.86M | 12.67M | 19.14M | 20.62M | 20.13M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -6.5M | 294K | -5.06M | -5.8M | -8.15M |
| Investing cash flow | -2.45M | -30.97M | 0 | 5.71M | 18.23M |
| Financing cash flow | -27K | 44.85M | -1.01M | 188K | -3.73M |
| Change in cash | -8.97M | 14.17M | -6.07M | 105K | 6.35M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 8-K — Rani Therapeutics Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13D/A — Rani Therapeutics Holdings, Inc. | View Filing | |
| form 4 | Form 4 — IMRAN MIR A | View Filing | |
| form 4 | Form 4 — BUTEL JEAN LUC | View Filing | |
| form 4 | Form 4 — Ausiello Dennis A | View Filing | |
| form 4 | Form 4 — Bassan Abraham | View Filing | |
| form 4 | Form 4 — Rometty Lisa Ann | View Filing | |
| form 4 | Form 4 — Bailey Vasudev Jaiprakash | View Filing | |
| edgar index | 424B5 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 8-K — Rani Therapeutics Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 10-Q — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Rani Therapeutics Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | DEFA14A — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | ARS — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 3 — Rani Therapeutics Holdings, Inc. | View Filing | |
| form 3 | Form 3 — Javadi Alireza | View Filing | |
| form 3 | Form 3 — Javadi Alireza | View Filing | |
| form 3 | Form 3 — Javadi Alireza | View Filing | |
| form 3 | Form 3 — Javadi Alireza | View Filing | |
| form 3 | Form 3 — Javadi Alireza | View Filing | |
| form 3 | Form 3 — Javadi Alireza | View Filing | |
| form 3 | Form 3 — Javadi Alireza | View Filing | |
| edgar index | 8-K — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 10-K — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | S-8 — Rani Therapeutics Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13G — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 8-K — Rani Therapeutics Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14C — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 424B5 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | EFFECT — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | CORRESP — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | PRE 14C — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | D — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | S-3 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 8-K — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 10-Q — Rani Therapeutics Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | SCHEDULE 13D — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 3 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 8-K — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 3 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Rani Therapeutics Holdings, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Rani Therapeutics Holdings, Inc. | View Filing | |
| form 4 | Form 4 — IMRAN MIR A | View Filing | |
| form 4 | Form 4 — IMRAN MIR A | View Filing | |
| form 4 | Form 4 — IMRAN MIR A | View Filing | |
| form 4 | Form 4 — IMRAN MIR A | View Filing | |
| form 4 | Form 4 — Bassan Abraham | View Filing | |
| form 4 | Form 4 — Bailey Vasudev Jaiprakash | View Filing | |
| edgar index | 4 — Rani Therapeutics Holdings, Inc. | View Filing |